Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.

Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Arellano J, Howard HH, Peyton M, Matar S, Liu X, Fowler AJ, Schwartz SL, Ahn J, Moussa C.

Pharmacol Res Perspect. 2019 Mar 12;7(2):e00470. doi: 10.1002/prp2.470. eCollection 2019 Apr.

2.

Improving estimation of puma (Puma concolor) population density: clustered camera-trapping, telemetry data, and generalized spatial mark-resight models.

Murphy SM, Wilckens DT, Augustine BC, Peyton MA, Harper GC.

Sci Rep. 2019 Mar 14;9(1):4590. doi: 10.1038/s41598-019-40926-7.

3.

Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis.

Bansal M, He J, Peyton M, Kustagi M, Iyer A, Comb M, White M, Minna JD, Califano A.

PLoS One. 2019 Jan 7;14(1):e0208646. doi: 10.1371/journal.pone.0208646. eCollection 2019.

4.

Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.

Mender I, LaRanger R, Luitel K, Peyton M, Girard L, Lai TP, Batten K, Cornelius C, Dalvi MP, Ramirez M, Du W, Wu LF, Altschuler SJ, Brekken R, Martinez ED, Minna JD, Wright WE, Shay JW.

Neoplasia. 2018 Aug;20(8):826-837. doi: 10.1016/j.neo.2018.06.002. Epub 2018 Jul 6.

5.

Low-Level Vagus Nerve Stimulation Suppresses Post-Operative Atrial Fibrillation and Inflammation: A Randomized Study.

Stavrakis S, Humphrey MB, Scherlag B, Iftikhar O, Parwani P, Abbas M, Filiberti A, Fleming C, Hu Y, Garabelli P, McUnu A, Peyton M, Po SS.

JACC Clin Electrophysiol. 2017 Sep;3(9):929-938. doi: 10.1016/j.jacep.2017.02.019. Epub 2017 May 30.

6.

Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.

McMillan EA, Ryu MJ, Diep CH, Mendiratta S, Clemenceau JR, Vaden RM, Kim JH, Motoyaji T, Covington KR, Peyton M, Huffman K, Wu X, Girard L, Sung Y, Chen PH, Mallipeddi PL, Lee JY, Hanson J, Voruganti S, Yu Y, Park S, Sudderth J, DeSevo C, Muzny DM, Doddapaneni H, Gazdar A, Gibbs RA, Hwang TH, Heymach JV, Wistuba I, Coombes KR, Williams NS, Wheeler DA, MacMillan JB, Deberardinis RJ, Roth MG, Posner BA, Minna JD, Kim HS, White MA.

Cell. 2018 May 3;173(4):864-878.e29. doi: 10.1016/j.cell.2018.03.028. Epub 2018 Apr 19.

7.

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.

Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA.

J Clin Invest. 2018 Jun 1;128(6):2500-2518. doi: 10.1172/JCI96148. Epub 2018 May 7.

8.

Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients.

Hocker JR, Deb SJ, Li M, Lerner MR, Lightfoot SA, Quillet AA, Hanas RJ, Reinersman M, Thompson JL, Vu NT, Kupiec TC, Brackett DJ, Peyton MD, Dubinett SM, Burkhart HM, Postier RG, Hanas JS.

Cancer Invest. 2017 Oct 21;35(9):573-585. doi: 10.1080/07357907.2017.1373120. Epub 2017 Sep 26.

PMID:
28949774
9.

Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models.

Hebron M, Peyton M, Liu X, Gao X, Wang R, Lonskaya I, Moussa CE.

J Neuroimmunol. 2017 Oct 15;311:1-9. doi: 10.1016/j.jneuroim.2017.07.009. Epub 2017 Aug 12.

PMID:
28863860
10.
11.

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.

Tagal V, Wei S, Zhang W, Brekken RA, Posner BA, Peyton M, Girard L, Hwang T, Wheeler DA, Minna JD, White MA, Gazdar AF, Roth MG.

Nat Commun. 2017 Jan 19;8:14098. doi: 10.1038/ncomms14098.

12.

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.

Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA.

Cancer Cell. 2016 Dec 12;30(6):940-952. doi: 10.1016/j.ccell.2016.11.006.

13.

PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.

Zhou X, Updegraff BL, Guo Y, Peyton M, Girard L, Larsen JE, Xie XJ, Zhou Y, Hwang TH, Xie Y, Rodriguez-Canales J, Villalobos P, Behrens C, Wistuba II, Minna JD, O'Donnell KA.

Cancer Res. 2017 Jan 1;77(1):187-197. doi: 10.1158/0008-5472.CAN-16-1267-T. Epub 2016 Nov 7.

14.

Intravenous leiomyomatosis disguised as a large deep vein thrombosis.

Gunderson CC, Parsons B, Penaroza S, Peyton MD, Landrum LM.

J Radiol Case Rep. 2016 May 31;10(5):29-35. eCollection 2016 May.

15.

A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Thu KL, Papari-Zareei M, Stastny V, Song K, Peyton M, Martinez VD, Zhang YA, Castro IB, Varella-Garcia M, Liang H, Xing C, Kittler R, Milchgrub S, Castrillon DH, Davidson HL, Reynolds CP, Lam WL, Lea J, Gazdar AF.

Oncotarget. 2016 Jun 10;8(31):50489-50499. doi: 10.18632/oncotarget.9929. eCollection 2017 Aug 1.

16.

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.

Frink RE, Peyton M, Schiller JH, Gazdar AF, Shay JW, Minna JD.

Oncotarget. 2016 May 31;7(22):31639-51. doi: 10.18632/oncotarget.9335.

17.

Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer.

Young JH, Peyton M, Seok Kim H, McMillan E, Minna JD, White MA, Marcotte EM.

Bioinformatics. 2016 May 1;32(9):1373-9. doi: 10.1093/bioinformatics/btw010. Epub 2016 Jan 10.

18.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV.

Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11.

19.

Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.

Hocker JR, Postier RG, Li M, Lerner MR, Lightfoot SA, Peyton MD, Deb SJ, Baker CM, Williams TL, Hanas RJ, Stowell DE, Lander TJ, Brackett DJ, Hanas JS.

Cancer Lett. 2015 Apr 10;359(2):314-24. doi: 10.1016/j.canlet.2015.01.035. Epub 2015 Jan 28.

20.

Genome-wide association study identifies variants in casein kinase II (CSNK2A2) to be associated with leukocyte telomere length in a Punjabi Sikh diabetic cohort.

Saxena R, Bjonnes A, Prescott J, Dib P, Natt P, Lane J, Lerner M, Cooper JA, Ye Y, Li KW, Maubaret CG, Codd V, Brackett D, Mirabello L, Kraft P, Dinney CP, Stowell D, Peyton M, Ralhan S, Wander GS, Mehra NK, Salpea KD, Gu J, Wu X, Mangino M, Hunter DJ, De Vivo I, Humphries SE, Samani NJ, Spector TD, Savage SA, Sanghera DK.

Circ Cardiovasc Genet. 2014 Jun;7(3):287-95. doi: 10.1161/CIRCGENETICS.113.000412. Epub 2014 May 3.

21.

Two different presentations of sinus of valsalva aneurysm.

Patel N, Rousan TA, Peyton MD, Sivaram CA.

Echocardiography. 2014 Jul;31(6):E181-4. doi: 10.1111/echo.12593. Epub 2014 Mar 25.

PMID:
24661120
22.

Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.

Hanas JS, Peyton MD, Lerner MR, Lightfoot SA, Deb SJ, Hanas RJ, Vu NT, Kupiec TC, Stowell DE, Brackett DJ, Dubinett SM, Hocker JR.

Cancer Invest. 2014 May;32(4):136-43. doi: 10.3109/07357907.2014.883528. Epub 2014 Feb 28.

PMID:
24579933
23.

Integrative analysis of two cell lines derived from a non-small-lung cancer patient--a panomics approach.

Mayba O, Gnad F, Peyton M, Zhang F, Walter K, Du P, Huntley MA, Jiang Z, Liu J, Haverty PM, Gentleman RC, Li R, Minna JD, Li Y, Shames DS, Zhang Z.

Pac Symp Biocomput. 2014:75-86.

24.

Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.

Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MA.

Cell. 2013 Oct 24;155(3):552-66. doi: 10.1016/j.cell.2013.09.041. Epub 2013 Oct 24.

25.

Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.

Blumenschein GR Jr, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J Jr, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM.

Clin Cancer Res. 2013 Dec 15;19(24):6967-75. doi: 10.1158/1078-0432.CCR-12-1818. Epub 2013 Oct 28.

26.

EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.

Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, Grishin NV, Peyton M, Minna J, Bhagat G, Levine B.

Cell. 2013 Sep 12;154(6):1269-84. doi: 10.1016/j.cell.2013.08.015.

27.

Distinct transcriptome profiles identified in normal human bronchial epithelial cells after exposure to γ-rays and different elemental particles of high Z and energy.

Ding LH, Park S, Peyton M, Girard L, Xie Y, Minna JD, Story MD.

BMC Genomics. 2013 Jun 1;14:372. doi: 10.1186/1471-2164-14-372.

28.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.

Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.

29.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV.

Cancer Discov. 2012 Sep;2(9):798-811. doi: 10.1158/2159-8290.CD-12-0112. Epub 2012 Sep 6.

30.

Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.

Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N.

Mol Cancer Ther. 2012 Nov;11(11):2473-82. doi: 10.1158/1535-7163.MCT-12-0431. Epub 2012 Aug 28.

31.

Isolated right ventricular infarction after modified Cabrol operation.

Pappy RM, Hanna EB, Peyton MD, Saucedo JF.

Tex Heart Inst J. 2012;39(1):133-7. Review.

32.

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.

Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL, Girard L, Martinez ED.

Br J Cancer. 2012 Jan 3;106(1):116-25. doi: 10.1038/bjc.2011.532. Epub 2011 Dec 8.

33.

Distinguishing non-small cell lung adenocarcinoma patients from squamous cell carcinoma patients and control individuals using serum profiling.

Hocker JR, Peyton MD, Lerner MR, Lightfoot SA, Hanas RJ, Brackett DJ, Hanas JS.

Cancer Invest. 2012 Feb;30(2):180-8. doi: 10.3109/07357907.2011.633294. Epub 2011 Dec 7.

PMID:
22149138
34.

Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals.

Hocker JR, Bishop EA, Lightfoot SA, Lerner MR, Peyton MD, Brackett DJ, Hanas RJ, McMeekin DS, Walker JL, Hanas JS.

Cancer Invest. 2012 Feb;30(2):189-97. doi: 10.3109/07357907.2011.636115. Epub 2011 Dec 7.

PMID:
22149058
35.

SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.

Greer RM, Peyton M, Larsen JE, Girard L, Xie Y, Gazdar AF, Harran P, Wang L, Brekken RA, Wang X, Minna JD.

Cancer Res. 2011 Dec 15;71(24):7640-8. doi: 10.1158/0008-5472.CAN-10-3947. Epub 2011 Nov 2.

36.

Abdominal aortic aneurysms (AAA) post heart transplantation: a systematic review of literature.

Dasari T, Heroux A, Peyton M, Saucedo J.

Ann Transplant. 2011 Jul-Sep;16(3):147-52. Review.

PMID:
21959525
37.

Direct sequencing in cytological specimens as a useful strategy for detecting EGFR mutations in non-small cell lung cancer patients.

Cho MC, Choi CM, Kim S, Jang S, Jang S, Park CJ, Chi HS, Peyton MJ, Lee W, Chun S, Kim SW, Min WK.

Clin Chem Lab Med. 2011 Sep 8;50(3):565-72. doi: 10.1515/CCLM.2011.704.

PMID:
21899495
38.

Cytogenetic and comparative genomic hybridization studies of an esophageal giant fibrovascular polyp: a case report.

Yu Z, Bane BL, Lee JY, Pitha JV, Peyton M, Houck J, Li S.

Hum Pathol. 2012 Feb;43(2):293-8. doi: 10.1016/j.humpath.2011.04.022. Epub 2011 Aug 10.

PMID:
21835434
39.

Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry.

Hocker JR, Peyton MD, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Bates-Albers LM, Vu NT, Hanas RJ, Kupiec TC, Brackett DJ, Hanas JS.

Lung Cancer. 2011 Nov;74(2):206-11. doi: 10.1016/j.lungcan.2011.03.014. Epub 2011 May 6.

PMID:
21529985
40.

STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.

Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, Fang B, Roth JA.

Cancer Res. 2011 May 15;71(10):3658-68. doi: 10.1158/0008-5472.CAN-10-3647. Epub 2011 Mar 28.

41.

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD.

Mol Cancer Ther. 2011 Feb;10(2):336-46. doi: 10.1158/1535-7163.MCT-10-0750.

42.

Distinguishing early-stage pancreatic cancer patients from disease-free individuals using serum profiling.

Hocker JR, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Quillet AA, Hanas RJ, Peyton MD, Postier RG, Brackett DJ, Hanas JS.

Cancer Invest. 2011 Feb;29(2):173-9. doi: 10.3109/07357907.2010.543214.

PMID:
21261478
43.

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.

Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA.

PLoS One. 2010 Nov 29;5(11):e14124. doi: 10.1371/journal.pone.0014124.

44.

Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.

Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD.

Cancer Res. 2010 Aug 15;70(16):6477-85. doi: 10.1158/0008-5472.CAN-10-0005. Epub 2010 Jul 27.

45.

Prolonged postsurgical survival without a pulmonic valve: case report and review of the literature.

Te CC, Bauer CE, Abu-Fadel MS, Peyton M, Sivaram CA.

Clin Cardiol. 2010 Jun;33(6):E1-5. doi: 10.1002/clc.20699. Review.

46.

Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.

Petersen SL, Peyton M, Minna JD, Wang X.

Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11936-41. doi: 10.1073/pnas.1005667107. Epub 2010 Jun 14.

47.

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.

Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M.

Am J Pathol. 2010 Jul;177(1):415-23. doi: 10.2353/ajpath.2010.090863. Epub 2010 May 20.

48.

Linear left atrial lesions in minimally invasive surgical ablation of persistent atrial fibrillation: techniques for assessing conduction block across surgical lesions.

Lockwood D, Nakagawa H, Peyton MD, Edgerton JR, Scherlag BJ, Sivaram CA, Po SS, Beckman KJ, Abedin M, Jackman WM.

Heart Rhythm. 2009 Dec;6(12 Suppl):S50-63. doi: 10.1016/j.hrthm.2009.09.010. Epub 2009 Sep 12.

PMID:
19959145
49.

Protection against chronic pancreatitis and pancreatic fibrosis in mice overexpressing pancreatic secretory trypsin inhibitor.

Nathan JD, Romac J, Peng RY, Peyton M, Rockey DC, Liddle RA.

Pancreas. 2010 Jan;39(1):e24-30. doi: 10.1097/MPA.0b013e3181bc45e9.

50.

MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells.

Guthi JS, Yang SG, Huang G, Li S, Khemtong C, Kessinger CW, Peyton M, Minna JD, Brown KC, Gao J.

Mol Pharm. 2010 Feb 1;7(1):32-40. doi: 10.1021/mp9001393.

Supplemental Content

Loading ...
Support Center